Ritter Pharmaceuticals, Inc. Prices $23,000,000 Public Offering
2017年9月29日 - 9:00PM
Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter
Pharmaceuticals” or the “Company”), a leading developer of novel
therapeutic products that modulate the human gut microbiome to
treat gastrointestinal diseases with an initial focus on developing
the first FDA approved treatment for lactose intolerance, today
announced the pricing of an underwritten public offering with
expected total gross proceeds of approximately $23,000,000, before
deducting underwriting discounts, commissions and other offering
expenses payable by the Company.
The securities offered by the Company consist of (i) Class A
Units consisting of 34,550,000 shares of our Common Stock and
Warrants to purchase 34,550,000 shares of Common Stock, and (ii)
Class B Units consisting of 9,180 shares of our Series A
Convertible Preferred Stock, with a stated value of $1,000, and
convertible into an aggregate of 22,950,000 shares of Common Stock,
and Warrants exercisable for the number of shares of Common Stock
into which the shares of Series A Convertible Preferred Stock are
convertible. The Warrants will have an exercise price of $0.44,
will be exercisable upon issuance and will expire five years from
the date of issuance. The Company has granted the underwriters a
45-day option to purchase additional shares of Common Stock and/or
additional Warrants to purchase shares of Common Stock, in amounts
up to 15% of the Common Stock, Warrants and/or Common Stock
issuable upon conversion of the Series A Preferred included in the
Class B Units sold in the offering.
The offering is expected to close on October 3, 2017, subject to
customary closing conditions.
Aegis Capital Corp. is acting as the sole book-running manager
for the offering.
A registration statement relating to these securities has been
filed with the Securities and Exchange Commission (the “SEC”) and
was declared effective on September 28, 2017.
The offering will be made only by means of a
prospectus. A copy of the prospectus relating to the offering may
be obtained, when available, by contacting Aegis Capital Corp.,
Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY
10019, telephone: 212-813-1010, e-mail: prospectus@aegiscap.com.
Investors may also obtain these documents at no cost by visiting
the SEC's website at http://www.sec.gov. This press release shall
not constitute an offer to sell or the solicitation of an offer to
buy nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc. (www.RitterPharma.com,
@RitterPharma) develops novel therapeutic products that modulate
the gut microbiome to treat gastrointestinal diseases. Its lead
product, RP-G28, has the potential to become the first FDA-approved
treatment for lactose intolerance, a condition that affects
millions worldwide. The Company is further exploring the
functionality and discovering the therapeutic potential gut
microbiome changes may have on treating/preventing a variety of
conditions including: gastrointestinal diseases, immuno-oncology,
metabolic, and liver disease.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements regarding the intended terms of the
offering, closing of the offering and use of any proceeds from the
offering. Management believes that these forward-looking statements
are reasonable as and when made. However, such statements
involve a number of known and unknown risks and uncertainties that
could cause the Company’s future results, performance or
achievements to differ significantly from the results, performance
or achievements expressed or implied by such forward-looking
statements. For a discussion of certain risks and uncertainties
affecting Ritter Pharmaceuticals’ forward-looking statements,
please review the Company’s reports filed with the Securities and
Exchange Commission, including, but not limited to, its Annual
Report on Form 10-K for the period ended December 31, 2016 and
Quarterly Reports on Form 10-Q for the periods ended March 31, 2017
and June 30, 2017. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date on which they are made. These statements are based on
management’s current expectations and Ritter Pharmaceuticals does
not undertake any responsibility to revise or update any
forward-looking statements contained herein, except as expressly
required by law.
Contact
Ellen Mochizuki
310-203-1000
ellen@ritterpharma.com
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 6 2024 まで 7 2024
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 7 2023 まで 7 2024